中源协和：治疗特发性肺纤维化（IPF）已完成I期所有受试者给药，正开展临床安全性、有效性数据整理

Group 1 - The company has completed all dosing for the Phase I clinical trial of VUM02 for the treatment of idiopathic pulmonary fibrosis (IPF) [2] - The company is currently organizing clinical safety and efficacy data following the completion of the Phase I trial [2] - Future updates regarding the clinical trial progress will be provided through company announcements and regular reports [2]